
|Articles|November 1, 2004
Plans review pediatric antidepressant use in wake of FDA label change
By withholding information about some antidepressant medications that cause an increase in suicidal tendencies among teenagers, the Food and Drug Administration (FDA) created heightened public concern about the value of antidepressants.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
2
What IRA drug prices will mean for PBMs, health plans and patients
3
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
4
Biosimilars in 2025: A year of firsts
5





















































